What’s Fueling Rocket Pharmaceuticals Inc (RCKT) Stock’s -33.36% Loss Below Its 200-Day SMA?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
What Factors Have Led to Rocket Pharmaceuticals Inc (RCKT) Stock Trading -47.36% Below Its 52-Week High?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Rocket Pharmaceuticals Inc (RCKT) Stock: More Resilient Than It Appears
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Why Did Rocket Pharmaceuticals Inc (RCKT) Stock Tumble -1.93% to $19.78?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Rocket Pharmaceuticals Inc (RCKT) Stock Rated Neutral by Goldman
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
The Rocket Pharmaceuticals Inc Stock Thriller: Decoding the Mystery Behind RCKT’s Recent Movements
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Rocket Pharmaceuticals Inc (RCKT) Stock: Greater Than Its Current Valuation?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Why Did Rocket Pharmaceuticals Inc (RCKT) Stock Tumble -2.25% to $19.1?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $45. Additionally, Canaccord Genuity […]
Rocket Pharmaceuticals Inc (RCKT) Stock Rated Neutral by Goldman
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral rating, as announced on April 2, 2024, according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65. Morgan Stanley also initiated Overweight rating with a price target of $$45. Additionally, Canaccord Genuity […]
Rocket Pharmaceuticals Inc (RCKT) Stock Sees Market Value Hit $1.76 billion: What Are the Implications?
Goldman has recently initiated Rocket Pharmaceuticals Inc (RCKT) stock to Neutral, as announced on April 2, 2024 according to Finviz. Earlier, on October 24, 2023, Cantor Fitzgerald had initiated the stock to Overweight, setting a price target of $65 Morgan Stanley also initiated Overweight rating with a price target range from to $45. Additionally, Canaccord […]
